A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Must be in good health, as determined by no clinically significant deviations from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations * Must have a body mass index (BMI) of 18.0 kg/m\^2 to 32.0 kg/m\^2, inclusive, at screening. BMI = weight (kg)/height (m)\^2 * Must have normal renal function at screening (and study admission) as evidenced by an estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73 m\^2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula Exclusion Criteria: * Any significant acute or chronic medical illness * Presence or need for urinary catheterization, urinary tract abnormality, or disorder interfering with urination * History of tinnitus or hearing impairment, including deafness * History or risks factors for Torsade de Pointes and Long QT syndrome (such as electrolyte imbalances, etc) * History of, or active, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection * Consumption of caffeine or xanthine-containing food or beverages within 72 hours prior to study treatment administration * Use of any prescription drugs or over-the-counter (OTC) acid controllers within 4 weeks prior to study treatment administration except those medications cleared by the Medical Monitor * Use of any other drugs, including …